Sun Pharma forecasts high single-digit revenue growth for FY27 after an 11.9% increase in FY26 revenue. The company aims to expand its innovative portfolio amid regulatory challenges and compliance issues, while also focusing on acquisitions and new product launches in the obesity-drug market.
​Sun Pharma forecasts high single-digit revenue growth for FY27 after an 11.9% increase in FY26 revenue. The company aims to expand its innovative portfolio amid regulatory challenges and compliance issues, while also focusing on acquisitions and new product launches in the obesity-drug market. by Soban News (international And National News)
